Showing posts with label Oncology. Show all posts
Showing posts with label Oncology. Show all posts

Monday, 8 January 2018

Global Revenue For The Oncology Market Is Forecast To Grow At A Compound Annual Growth Rate (CAGR) Of 10.66%, To $241.0 Billion In 2023

Researchmoz added Most up-to-date research on "Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors" to its huge collection of research reports.

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic. However, they exert more damage on malignant tissue than healthy tissue due to the rapid cell cycle of cancer cells. The key cancer indications of this report are breast, colorectal, lung, and prostate and hematological cancers.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1245341

A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Scope

- Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?
- What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?
- How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?
- What proportion of the key players’ revenues will be attributable to oncology products?

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-oncology-market-to-2023-robust-growth-driven-by-rising-prevalence-and-increased-uptake-of-immune-checkpoint-inhibitors-report.html/toc

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types
- Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers
- Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals

Thursday, 20 July 2017

Global Revenue For The Oncology Market Is Forecast To Grow At A CAGR Of 10.66%, From $118.6 Billion In 2016 To $241.0 Billion In 2023

Researchmoz added Most up-to-date research on "Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors" to its huge collection of research reports.

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic. However, they exert more damage on malignant tissue than healthy tissue due to the rapid cell cycle of cancer cells. The key cancer indications of this report are breast, colorectal, lung, and prostate and hematological cancers.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1245341

A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Browse Detail Report With TOC @ http://www.researchmoz.us/global-oncology-market-to-2023-robust-growth-driven-by-rising-prevalence-and-increased-uptake-of-immune-checkpoint-inhibitors-report.html

Scope

- Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?
- What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?
- How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?
- What proportion of the key players’ revenues will be attributable to oncology products?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types
- Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers
- Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 11
2.3 Diagnosis 12
2.4 Etiology and Pathophysiology 13
2.4.1 Etiology 13
2.4.2 Pathophysiology 15
2.5 Co-morbidities and Complications 16
2.6 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 17
2.6.1 Breast Cancer 17
2.6.2 Colorectal Cancer 18
2.6.3 Lung Cancer 19
2.6.4 Prostate Cancer 20
2.6.5 Hematological Cancers 21
2.7 Prognosis 22
2.7.1 Breast Cancer 22
2.7.2 Colorectal Cancer 23
2.7.3 Non-Small-Cell Lung Cancer 23
2.7.4 Prostate Cancer 24
2.8 Treatment 25
2.8.1 Surgery and Radiation Therapy 25
2.8.2 Chemotherapy 26
2.8.3 Hormonal Therapies 28
2.8.4 Targeted Therapies 29

3 Key Marketed Products 31
3.1 Overview 31
3.2 MabThera/Rituxan (rituximab) 32
3.3 Avastin (bevacizumab) 33
3.4 Herceptin (trastuzumab) 35
3.5 Revlimid (lenalidomide) 37
3.6 Opdivo (nivolumab) 39
3.7 Xtandi (enzalutamide) 41
3.8 Gleevec/Glivec (imatinib mesylate) 42
3.9 Alimta (pemetrexed) 44
3.10 Zytiga (abiraterone acetate) 46
3.11 Conclusion 47

4 Pipeline Landscape Assessment 49
4.1 Overview 49
4.2 Pipeline Development Landscape 50
4.3 Molecular Targets in the Pipeline 54
4.4 Clinical Trials 58
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 58
4.4.2 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target 62
4.4.3 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target 66
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 70
4.4.5 Conclusion 74
4.5 Assessment of Key Pipeline Products 74
4.5.1 Durvalumab - AstraZeneca 74
4.5.2 Durvalumab and Tremelimumab - AstraZeneca 75
4.5.3 Abemaciclib - Eli Lilly 76
4.5.4 Rova-T (rovalpituzumab tesirine) - AbbVie 77
4.5.5 Neratinib - Puma Biotechnology 79
4.5.6 Acalabrutinib - AstraZeneca 80
4.5.7 KTE-C19 (Axicabtagene Ciloleucel) - Kite Pharma 81
4.5.8 Tisagenlecleucel-T - Novartis 83
4.5.9 Conclusion 84

5 Multi-scenario Market Forecast to 2023 85
5.1 Overall Market Size 85
5.2 Generic Penetration 101
5.3 Revenue Forecast by Molecular Target 103
5.3.1 Programmed Cell Death Protein 1/Programmed Cell Death 1 Ligand 1 103
5.3.2 Tumor Necrosis Factor 105
5.3.3 Tyrosine-Protein Kinase BTK 106
5.3.4 Cyclin-Dependent Kinases 107
5.3.5 Androgen Receptor 108
5.3.6 Vascular Endothelial Growth Factor 109

6 Company Analysis and Positioning 110
6.1 Revenue and Market Share Analysis by Company 111
6.1.1 Roche - To What Extent Will Newly Approved and Pipeline Product Approvals Offset the Patent Expiries of Avastin and Herceptin? 116
6.1.2 Celgene - How Will Multiple Patent Expiries Affect Oncology-Related Revenues? 118
6.1.3 Novartis - How Will Mekinist plus Tafinlar and Tasigna Perform over the Forecast Period? 119
6.1.4 Bristol-Myers Squibb - How Successful Will Recent Approvals Opdivo and Empliciti Become? 120
6.1.5 Pfizer - What Do Sutent and Inlyta Patent Expiries Mean for Pfizer? 120
6.1.6 AstraZeneca - How Will its Immune Checkpoint Inhibitors Durvalumab and Tremelimumab Perform? 121
6.2 Company Landscape 123
6.3 Marketed and Pipeline Portfolio Analysis 124

7 Strategic Consolidations 126
7.1 Licensing Deals 126
7.1.1 Deals by Region, Year and Value 126
7.1.2 Deals by Stage of Development and Value 129
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 130
7.1.4 Table for Licensing Deals Valued Above $100m 131
7.2 Co-development Deals 145
7.2.1 Deals by Region, Year and Value 145
7.2.2 Deals by Stage of Development and Value 147
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 148
7.2.4 Table for Co-development Deals Valued $1 billion and Above 149

8 Appendix 156
8.1 References 156
8.2 Abbreviations 417
8.3 Methodology 418
8.3.1 Secondary Research 418
8.3.2 Market Size and Revenue Forecasts 419
8.3.3 Pipeline Analysis 419
8.3.4 Competitive Landscape 419
8.4 Contact Us 420
8.5 Disclaimer 420

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1245341

Sunday, 11 June 2017

Global Lymphoma Drugs Market To Grow At A CAGR Of 8.02% During The Period 2017-2021

Researchmoz added Most up-to-date research on "Global Lymphoma Drugs Market 2017-2021" to its huge collection of research reports.

Lymphoma is a type of cancer that affects the immune system of the body. Specifically, it affects the lymphocytes, a type of white blood cell. The lymphocytes are part of the immune system and help the body to fight infections. The cancerous lymphocytes grow uncontrollably and collect in different portions of the body; lymph node can be one of the most common sites for lymphoma development. The lymph nodes are found throughout the body particularly in the groin, neck, and under the arms. Lymphoma can also develop in the deeper lymph nodes such as those in bone marrow and spleen. Very rarely this disease can start in other parts of the body such as stomach, breast, skin, brain, bowel, or liver.

Technavios analysts forecast the global lymphoma drugs market to grow at a CAGR of 8.02% during the period 2017-2021.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1140719

Covered in this report
The report covers the present scenario and the growth prospects of the global lymphoma drugs market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Lymphoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Celgene
F. Hoffmann-La Roche
Johnson & Johnson
Seattle Genetics
Other prominent vendors
Amgen
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Novartis
Pfizer
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
Market driver
Increase in industry-academia collaborations
For a full, detailed list, view our report

Market challenge
High cost of lymphoma treatment
For a full, detailed list, view our report

Market trend
Increasing consolidation in the cancer treatment market
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1140719

Wednesday, 3 May 2017

Global CLL Therapeutics Market To Grow At A CAGR Of 19.16% During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports.

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
CLL

Technavios analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=729302

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffman-La Roche
AbbVie
Teva Pharmaceuticals
Gilead Sciences
Novartis
Johnson & Johnson

Other prominent vendors
Altor BioScience
Amgen
Arno Therapeutics
AstraZeneca
Bellicum Pharmaceuticals
Biogen
BioLineRx
Boston Biomedical
Celgene
Emergent BioSolutions
Genzyme
iDD biotech
Immunomedics
Infinity Pharmaceuticals
Innate Pharma
Karyopharm Therapeutics
Ligand Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Molecular Templates Inc.
MorphoSys
Ono Pharmaceutical
Portola Pharmaceuticals
Regeneron Pharmaceuticals
Sunesis Pharmaceuticals
TG Therapeutics
TheraMAB
XEME Biopharma
Xencor
ZIOPHARM Oncology

Market driver
Special regulatory designations
For a full, detailed list, view our report

Market challenge
High cost of therapy
For a full, detailed list, view our report

Market trend
Rise in development of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=729302

Wednesday, 22 March 2017

Versatile Innovation in Oncology Industry Key Trends, Size, Growth, Shares And Forecast Research Report

Researchmoz added Most up-to-date research on "Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation" to its huge collection of research reports.

The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484 products in active development across all oncology indications, and 2,084 first-in-class products in development across all stages.

Due to a degree of crossover between oncology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications. Some 473 first-in-class pipeline products are in concurrent development for two or more of the top 20 cancer sites ranked by incidence. The most promising versatile first-in-class molecular targets predominantly consist of receptor tyrosine kinases and their downstream signal transduction kinases, although a number of other cancer-related processes such as DNA repair, cancer immunosurveillance and apoptotic pathways are also targeted.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=316439

Scope

- With 6,484 products in active development across all oncology indications, this is the largest therapy area pipeline by a considerable margin.
- What factors are driving this high level of R&D activity?
- Which indications have the highest concentration of pipeline products?
- Although the unmet need varies between and within indications, this need is primarily for improved overall survival rates in patients, particularly those at the late stage of the disease.
- Which first-in-class molecular targets appear able to best address the key unmet needs within oncology?
- The variation in molecule type has shifted away from small molecules, the dominance of which has decreased from 94% across marketed products to 49% across the pipeline.
- What are the dynamics of the remaining 51% of the pipeline?
- How does this reflect the need for novel targeted therapies?
- There has been a significant shift towards inhibitors of receptor tyrosine kinases, their ligands and signal transduction proteins, as well as drugs targeted against cancer antigens.
- What is the scientific rationale behind these targets? Across which indications are they being developed?
- How successful have drugs against these targets been?
- A number of versatile first-in-class targets appear to be particularly promising, including HER3, FGFR3, telomerase reverse transcriptase, and others.
- Why are these targets considered to be particularly promising?
- Why are these targets being developed across such a wide range of indications?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options across the key oncology indications
- Acquire a detailed understanding of the 20 most common oncology indications by incidence, pinpointing the unmet needs for each indication
- Assess the market for oncology in terms of the molecular targets that are approved across multiple indications and the predominant molecule types and targets
- Analyze the oncology pipeline and stratify by stage of development, molecule type, molecular target, and first-in-class status
- Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are in development for
- Analyze the therapeutic potential and developmental footprint of versatile first-in-class targets and understand which are the most promising. Understand which targets are being developed in each indication, for how many pipeline products, and how well they align with the underlying pathophysiology of cancer
- Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals for versatile first-in-class products
- Identify versatile first-in-class pipeline products that have not been previously involved in licensing or co-development deals and are thus more likely to be available for in-licensing or co-development

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=316439

Monday, 23 January 2017

At A CAGR Of 19.16% CLL Therapeutics Global Industry Will Grow Steadily During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports.

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
CLL

Technavios analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=729302

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffman-La Roche
AbbVie
Teva Pharmaceuticals
Gilead Sciences
Novartis
Johnson & Johnson

Other prominent vendors
Altor BioScience
Amgen
Arno Therapeutics
AstraZeneca
Bellicum Pharmaceuticals
Biogen
BioLineRx
Boston Biomedical
Celgene
Emergent BioSolutions
Genzyme
iDD biotech
Immunomedics
Infinity Pharmaceuticals
Innate Pharma
Karyopharm Therapeutics
Ligand Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Molecular Templates Inc.
MorphoSys
Ono Pharmaceutical
Portola Pharmaceuticals
Regeneron Pharmaceuticals
Sunesis Pharmaceuticals
TG Therapeutics
TheraMAB
XEME Biopharma
Xencor
ZIOPHARM Oncology

Market driver
Special regulatory designations
For a full, detailed list, view our report

Market challenge
High cost of therapy
For a full, detailed list, view our report

Market trend
Rise in development of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=729302

Thursday, 19 January 2017

At A CAGR Of 19.16% CLL Therapeutics Global Industry Will Grow Steadily During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports.

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
CLL

Technavios analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=729302

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffman-La Roche
AbbVie
Teva Pharmaceuticals
Gilead Sciences
Novartis
Johnson & Johnson

Other prominent vendors
Altor BioScience
Amgen
Arno Therapeutics
AstraZeneca
Bellicum Pharmaceuticals
Biogen
BioLineRx
Boston Biomedical
Celgene
Emergent BioSolutions
Genzyme
iDD biotech
Immunomedics
Infinity Pharmaceuticals
Innate Pharma
Karyopharm Therapeutics
Ligand Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Molecular Templates Inc.
MorphoSys
Ono Pharmaceutical
Portola Pharmaceuticals
Regeneron Pharmaceuticals
Sunesis Pharmaceuticals
TG Therapeutics
TheraMAB
XEME Biopharma
Xencor
ZIOPHARM Oncology

Market driver
Special regulatory designations
For a full, detailed list, view our report

Market challenge
High cost of therapy
For a full, detailed list, view our report

Market trend
Rise in development of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=729302

Thursday, 15 December 2016

Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology | Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology" to its huge collection of research reports.

Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:

Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:
Negative Immune Checkpoints:


PD-1(programmed cell death 1
PD-L1(programmed cell death ligand 1 (PD-L1)
(Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
(Lymphocyte Activation Gene 3; CD223)
(T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
(V-region Ig-containing Suppressor of T-cell Activation) Receptor
(Carcino-Embryonic Antigen Cell Adhesion Molecule 1)
BTLA (B- and T-Lymphocyte Attenuator)
GARP (Glycoprotein A Repetitions Predominant)
TIGIT(T-cell Immunoreceptor with Ig and ITIM domains)
IL-10(Interleukin-10)
B7-H3(CD273)

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=895857

Stimulatory Immune Checkpoints:

CD40 (TNFSFR5)
GITR(Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
OX40(CD134; TNFSFR4)
4-1BB(CD137; TNFSFR9)
CD27 (TNFSFR7)
ICOS(Inducible Co-Stimulator)

Immunosuppressive tumor microenvironment:

IDO (Indoleamine 2,3-dioxygenase
TDO ( Tryptophan 2,3 dioxygenase)
TGF-B/R ( Transforming Growth Factor beta/Receptor)
CXCR4 (Chemokine Receptor Type 4)
CSF-1R ( Colony Stimulating Factor-1 Receptor)
CD47 SIRPa (Signal Regulatory Protein Alpha)
Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
STING (STimulator of INterferon Genes) Receptor
Others ( e.g. arginase)

More than 90 unique molecules (mostly antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further 31 molecules are undergoing IND-enabling studies.
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=895857

Blood Thawing System Market Insights Shared in Detailed Report

Blood Thawing System Market: Introduction According to the report, the global  blood thawing system market  was valued at ~US$ 174 Mn in 2...